Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2020 Filed Jun 23, 2020 01:17 UTC |
Howton David TEVP, General Counsel
|
Exercise / conversionStock option (right to buy) · Derivative | 56,984 | $0.00 Strike: $23.85 | $0.00 |
DisclosureSEC source: 0001209191-20-038339 · doc4.xml · derivative · entry 11 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56,984 shares Expires 2022-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 01:17 UTC |
Howton David TEVP, General Counsel
|
Exercise / conversionStock option (right to buy) · Derivative | 1,858 | $0.00 Strike: $13.71 | $0.00 |
DisclosureSEC source: 0001209191-20-038339 · doc4.xml · derivative · entry 10 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,858 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 01:17 UTC |
Howton David TEVP, General Counsel
|
Exercise / conversionStock option (right to buy) · Derivative | 1,280 | $0.00 Strike: $13.71 | $0.00 |
DisclosureSEC source: 0001209191-20-038339 · doc4.xml · derivative · entry 9 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,280 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 01:17 UTC |
Howton David TEVP, General Counsel
|
SaleCommon Stock | 55,270 | $171.50 | $9,478,805.00 |
DisclosureSEC source: 0001209191-20-038339 · doc4.xml · nonDerivative · entry 8 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,871 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. F5 · price: The shares were sold in transactions at prices ranging from $171.09 to $172.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 01:17 UTC |
Howton David TEVP, General Counsel
|
SaleCommon Stock | 35,757 | $170.59 | $6,099,786.63 |
DisclosureSEC source: 0001209191-20-038339 · doc4.xml · nonDerivative · entry 7 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,141 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. F4 · price: The shares were sold in transactions at prices ranging from $170.09 to $171.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 01:17 UTC |
Howton David TEVP, General Counsel
|
SaleCommon Stock | 8,086 | $169.56 | $1,371,062.16 |
DisclosureSEC source: 0001209191-20-038339 · doc4.xml · nonDerivative · entry 6 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,898 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. F3 · price: The shares were sold in transactions at prices ranging from $169.09 to $170.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 01:17 UTC |
Howton David TEVP, General Counsel
|
SaleCommon Stock | 6,009 | $168.61 | $1,013,177.49 |
DisclosureSEC source: 0001209191-20-038339 · doc4.xml · nonDerivative · entry 5 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,984 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. F2 · price: The shares were sold in transactions at prices ranging from $168.04 to $169.0399, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 01:17 UTC |
Howton David TEVP, General Counsel
|
Exercise / conversionCommon Stock | 45,000 | $29.03 | $1,306,350.00 |
DisclosureSEC source: 0001209191-20-038339 · doc4.xml · nonDerivative · entry 4 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,993 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 01:17 UTC |
Howton David TEVP, General Counsel
|
Exercise / conversionCommon Stock | 56,984 | $23.85 | $1,359,068.40 |
DisclosureSEC source: 0001209191-20-038339 · doc4.xml · nonDerivative · entry 3 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,993 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 01:17 UTC |
Howton David TEVP, General Counsel
|
Exercise / conversionCommon Stock | 1,858 | $13.71 | $25,473.18 |
DisclosureSEC source: 0001209191-20-038339 · doc4.xml · nonDerivative · entry 2 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,009 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 01:17 UTC |
Howton David TEVP, General Counsel
|
Exercise / conversionCommon Stock | 1,280 | $13.71 | $17,548.80 |
DisclosureSEC source: 0001209191-20-038339 · doc4.xml · nonDerivative · entry 1 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,151 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| May 20, 2020 Filed May 23, 2020 00:00 UTC |
Wigzell Hans Lennart RudolfDirector
|
Exercise / conversionStock Oprion (right to buy) · Derivative | 5,000 | $0.00 Strike: $10.08 | $0.00 |
DisclosureSEC source: 0001209191-20-031881 · doc4.xml · derivative · entry 5 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2022-08-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2020 Filed May 23, 2020 00:00 UTC |
Wigzell Hans Lennart RudolfDirector
|
SaleCommon Stock | 854 | $151.77 | $129,611.58 |
DisclosureSEC source: 0001209191-20-031881 · doc4.xml · nonDerivative · entry 4 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,792 F3 · price: The shares were sold in transactions at prices ranging from $151.67 to $151.75, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 20, 2020 Filed May 23, 2020 00:00 UTC |
Wigzell Hans Lennart RudolfDirector
|
SaleCommon Stock | 2,046 | $151.22 | $309,396.12 |
DisclosureSEC source: 0001209191-20-031881 · doc4.xml · nonDerivative · entry 3 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,646 F2 · price: The shares were sold in transactions at prices ranging from $150.62 to $151.62, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 20, 2020 Filed May 23, 2020 00:00 UTC |
Wigzell Hans Lennart RudolfDirector
|
SaleCommon Stock | 2,100 | $149.62 | $314,202.00 |
DisclosureSEC source: 0001209191-20-031881 · doc4.xml · nonDerivative · entry 2 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,692 F1 · price: The shares were sold in transactions at prices ranging from $149.11 to $149.89, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 20, 2020 Filed May 23, 2020 00:00 UTC |
Wigzell Hans Lennart RudolfDirector
|
Exercise / conversionCommon Stock | 5,000 | $10.08 | $50,400.00 |
DisclosureSEC source: 0001209191-20-031881 · doc4.xml · nonDerivative · entry 1 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2020 Filed May 16, 2020 01:02 UTC |
Barry RichardDirector
|
SaleCommon Stock | 4,673 | $142.05 | $663,799.65 |
DisclosureSEC source: 0001209191-20-029918 · doc4.xml · nonDerivative · entry 2 Barry Richard · CIK 0001562371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,159,140 F2 · price: The shares were sold in transactions at prices ranging from $142.00 to $142.30, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 15, 2020 Filed May 16, 2020 01:02 UTC |
Barry RichardDirector
|
SaleCommon Stock | 25,327 | $141.12 | $3,574,146.24 |
DisclosureSEC source: 0001209191-20-029918 · doc4.xml · nonDerivative · entry 1 Barry Richard · CIK 0001562371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,163,813 F1 · price: The shares were sold in transactions at prices ranging from $140.60 to $141.54, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 11, 2020 Filed Jul 10, 2020 00:00 UTC |
Mahatme SandeshEVP, CFO & CBO
|
GiftCommon Stock | 20,425 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-042060 · doc4.xml · nonDerivative · entry 1 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,454 F1 · kind: This transaction involved a gift of shares of common stock by the reporting person to family trusts. Read SEC document |
| March 04, 2020 Filed Mar 7, 2020 01:01 UTC |
Wigzell Hans Lennart RudolfDirector
|
Exercise / conversionStock option (right to buy) · Derivative | 5,000 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001209191-20-017097 · doc4.xml · derivative · entry 3 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2021-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2020 Filed Mar 7, 2020 01:01 UTC |
Wigzell Hans Lennart RudolfDirector
|
SaleCommon Stock | 5,000 | $116.89 | $584,450.00 |
DisclosureSEC source: 0001209191-20-017097 · doc4.xml · nonDerivative · entry 2 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,792 F1 · price: The shares were sold in multiple transactions at prices ranging from $116.8104 to $117.305, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 04, 2020 Filed Mar 7, 2020 01:01 UTC |
Wigzell Hans Lennart RudolfDirector
|
Exercise / conversionCommon Stock | 5,000 | $8.46 | $42,300.00 |
DisclosureSEC source: 0001209191-20-017097 · doc4.xml · nonDerivative · entry 1 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:07 UTC |
GRAY MARY ANNDirector
|
GrantStock option (right to buy) · Derivative | 3,685 | $0.00 Strike: $114.47 | $0.00 |
DisclosureSEC source: 0001209191-20-014239 · doc4.xml · derivative · entry 2 GRAY MARY ANN · CIK 0001261974 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,685 Underlying: Common Stock · 3,685 shares Expires 2030-02-28 Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:07 UTC |
GRAY MARY ANNDirector
|
GrantCommon Stock | 2,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014239 · doc4.xml · nonDerivative · entry 1 GRAY MARY ANN · CIK 0001261974 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,743 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on February 28, 2021. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on February 28, 2021. Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:06 UTC |
BONNEY MICHAEL WDirector
|
GrantStock option (right to buy) · Derivative | 3,685 | $0.00 Strike: $114.47 | $0.00 |
DisclosureSEC source: 0001209191-20-014237 · doc4.xml · derivative · entry 2 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,685 Underlying: Common Stock · 3,685 shares Expires 2030-02-28 Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:06 UTC |
BONNEY MICHAEL WDirector
|
GrantCommon Stock | 2,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014237 · doc4.xml · nonDerivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,126 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on February 28, 2021. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on February 28, 2021. Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:05 UTC |
Nicaise ClaudeDirector
|
GrantStock option (right to buy) · Derivative | 3,685 | $0.00 Strike: $114.47 | $0.00 |
DisclosureSEC source: 0001209191-20-014235 · doc4.xml · derivative · entry 2 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,685 Underlying: Common Stock · 3,685 shares Expires 2030-02-28 Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:05 UTC |
Nicaise ClaudeDirector
|
GrantCommon Stock | 2,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014235 · doc4.xml · nonDerivative · entry 1 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,126 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on February 28, 2021. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on February 28, 2021. Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:04 UTC |
Wigzell Hans Lennart RudolfDirector
|
GrantStock option (right to buy) · Derivative | 3,685 | $0.00 Strike: $114.47 | $0.00 |
DisclosureSEC source: 0001209191-20-014233 · doc4.xml · derivative · entry 2 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,685 Underlying: Common Stock · 3,685 shares Expires 2030-02-28 Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:04 UTC |
Wigzell Hans Lennart RudolfDirector
|
GrantCommon Stock | 2,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014233 · doc4.xml · nonDerivative · entry 1 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,792 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on February 28, 2021. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on February 28, 2021. Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:04 UTC |
Barry RichardDirector
|
GrantStock option (right to buy) · Derivative | 3,685 | $0.00 Strike: $114.47 | $0.00 |
DisclosureSEC source: 0001209191-20-014232 · doc4.xml · derivative · entry 2 Barry Richard · CIK 0001562371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,685 Underlying: Common Stock · 3,685 shares Expires 2030-02-28 Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:04 UTC |
Barry RichardDirector
|
GrantCommon Stock | 2,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014232 · doc4.xml · nonDerivative · entry 1 Barry Richard · CIK 0001562371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,189,140 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on February 28, 2021. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on February 28, 2021. Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:03 UTC |
BEHRENS M KATHLEENDirector
|
GrantStock option (right to buy) · Derivative | 3,685 | $0.00 Strike: $114.47 | $0.00 |
DisclosureSEC source: 0001209191-20-014231 · doc4.xml · derivative · entry 3 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,685 Underlying: Common Stock · 3,685 shares Expires 2030-02-28 Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:03 UTC |
BEHRENS M KATHLEENDirector
|
GrantCommon Stock | 2,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014231 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,742 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on February 28, 2021. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on February 28, 2021. Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:02 UTC |
MARTIN JOHN CDirector
|
GrantStock option (right to buy) · Derivative | 3,685 | $0.00 Strike: $114.47 | $0.00 |
DisclosureSEC source: 0001209191-20-014229 · doc4.xml · derivative · entry 4 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,685 Underlying: Common Stock · 3,685 shares Expires 2020-02-28 Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:02 UTC |
MARTIN JOHN CDirector
|
GrantStock option (right to buy) · Derivative | 5,528 | $0.00 Strike: $114.47 | $0.00 |
DisclosureSEC source: 0001209191-20-014229 · doc4.xml · derivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,528 Underlying: Common Stock · 5,528 shares Expires 2020-02-28 F3 · derivative.exercise_date: The option vests in three equal annual installments beginning February 28, 2021. Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:02 UTC |
MARTIN JOHN CDirector
|
GrantCommon Stock | 2,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014229 · doc4.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,187 F2 · shares: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on February 28, 2021. F2 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on February 28, 2021. Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:02 UTC |
MARTIN JOHN CDirector
|
GrantCommon Stock | 3,112 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014229 · doc4.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,112 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs vest in three equal annual installments beginning February 28, 2021. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs vest in three equal annual installments beginning February 28, 2021. Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:02 UTC |
O'Neill Gilmore NeilEVP, R&D & CMO
|
GrantStock option (right to buy) · Derivative | 37,500 | $0.00 Strike: $114.47 | $0.00 |
DisclosureSEC source: 0001209191-20-014228 · doc4.xml · derivative · entry 2 O'Neill Gilmore Neil · CIK 0001742084 · EVP, R&D & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2030-02-28 F2 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:02 UTC |
O'Neill Gilmore NeilEVP, R&D & CMO
|
GrantCommon Stock | 6,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014228 · doc4.xml · nonDerivative · entry 1 O'Neill Gilmore Neil · CIK 0001742084 · EVP, R&D & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,070 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest and become exercisable on the first anniversary of the grant date, and additional 25% will vest and become exercisable on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested and exercisable on the fourth anniversary of the grant date. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest and become exercisable on the first anniversary of the grant date, and additional 25% will vest and become exercisable on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested and exercisable on the fourth anniversary of the grant date. Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:01 UTC |
Cumbo AlexanderEVP, Chief Commercial Officer
|
GrantStock option (right to buy) · Derivative | 37,500 | $0.00 Strike: $114.47 | $0.00 |
DisclosureSEC source: 0001209191-20-014226 · doc4.xml · derivative · entry 3 Cumbo Alexander · CIK 0001685994 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2030-02-28 F2 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:01 UTC |
Cumbo AlexanderEVP, Chief Commercial Officer
|
GrantCommon Stock | 6,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014226 · doc4.xml · nonDerivative · entry 1 Cumbo Alexander · CIK 0001685994 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,567 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest and become exercisable on the first anniversary of the grant date, and additional 25% will vest and become exercisable on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested and exercisable on the fourth anniversary of the grant date. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest and become exercisable on the first anniversary of the grant date, and additional 25% will vest and become exercisable on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested and exercisable on the fourth anniversary of the grant date. Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:01 UTC |
Howton David TEVP, General Counsel
|
GrantStock option (right to buy) · Derivative | 37,500 | $0.00 Strike: $114.47 | $0.00 |
DisclosureSEC source: 0001209191-20-014224 · doc4.xml · derivative · entry 2 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2030-02-28 F2 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:01 UTC |
Howton David TEVP, General Counsel
|
GrantCommon Stock | 6,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014224 · doc4.xml · nonDerivative · entry 1 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,871 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest and become exercisable on the first anniversary of the grant date, and additional 25% will vest and become exercisable on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested and exercisable on the fourth anniversary of the grant date. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest and become exercisable on the first anniversary of the grant date, and additional 25% will vest and become exercisable on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested and exercisable on the fourth anniversary of the grant date. Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:00 UTC |
Mahatme SandeshEVP, CFO & CBO
|
GrantStock option (right to buy) · Derivative | 37,500 | $0.00 Strike: $114.47 | $0.00 |
DisclosureSEC source: 0001209191-20-014223 · doc4.xml · derivative · entry 3 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2030-02-28 F2 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:00 UTC |
Mahatme SandeshEVP, CFO & CBO
|
GrantCommon Stock | 6,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014223 · doc4.xml · nonDerivative · entry 1 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,879 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest and become exercisable on the first anniversary of the grant date, and additional 25% will vest and become exercisable on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested and exercisable on the fourth anniversary of the grant date. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest and become exercisable on the first anniversary of the grant date, and additional 25% will vest and become exercisable on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested and exercisable on the fourth anniversary of the grant date. Read SEC document |
| December 31, 2019 Filed Jan 4, 2020 01:00 UTC |
INGRAM DOUGLAS SDirector · President & CEO
|
Tax withholdingCommon Stock | 37,185 | $129.04 | $4,798,352.40 |
DisclosureSEC source: 0001209191-20-001424 · doc4.xml · nonDerivative · entry 1 INGRAM DOUGLAS S · CIK 0001190644 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 395,012 F1 · kind: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of a restricted stock award granted on June 26, 2017. F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of a restricted stock award granted on June 26, 2017. F1 · acquired: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of a restricted stock award granted on June 26, 2017. Read SEC document |
| December 13, 2019 Filed Dec 18, 2019 01:00 UTC |
Mahatme SandeshEVP, CFO & CBO
|
Exercise / conversionStock option (right to buy) · Derivative | 14,723 | $0.00 Strike: $34.92 | $0.00 |
DisclosureSEC source: 0001209191-19-061048 · doc4.xml · derivative · entry 14 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,277 Underlying: Common Stock · 14,723 shares Expires 2023-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| December 13, 2019 Filed Dec 18, 2019 01:00 UTC |
Mahatme SandeshEVP, CFO & CBO
|
Exercise / conversionStock option (right to buy) · Derivative | 21,875 | $0.00 Strike: $32.63 | $0.00 |
DisclosureSEC source: 0001209191-19-061048 · doc4.xml · derivative · entry 13 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,874 Underlying: Common Stock · 21,875 shares Expires 2027-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| December 13, 2019 Filed Dec 18, 2019 01:00 UTC |
Mahatme SandeshEVP, CFO & CBO
|
Exercise / conversionStock option (right to buy) · Derivative | 69,479 | $0.00 Strike: $29.03 | $0.00 |
DisclosureSEC source: 0001209191-19-061048 · doc4.xml · derivative · entry 12 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 69,479 shares Expires 2024-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.